https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2849653/SimilarApr 7, 2009 . An EGFR independence signature in H1650 cells. A, hierarchical clustering of 53 NSCLC cells according to gene expression. Erlotinib sensitivity (IC50 < 1 μmol/L, red; IC50 > 1 μmol/L, gray) and EGFR mutations (EGFR-mutant, black; T790M, red; EGFR wild-type, gray) as well as MET amplification (black).

www.oncotarget.com/fulltext/17625CachedJul 18, 2017 . Treatment of EGFR mutant cell lines with a pan-JAK inhibitor . . Similarly, neither

https://meetinglibrary.asco.org/record/96538/abstractCachedThough most patients with EGFR activating mutation response to EGFR-TKI, .

https://library.iaslc.org/search-speaker?search_speaker=30519CachedRecently, we reported a distinct mechanism of acquired resistance whereby

agris.fao.org/agris-search/search.do?recordID=US201301845382CachedCombined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung

repository.cshl.edu/26252/1/Sordella%20PNAS%202005.pdfCachedMay 24, 2005 . NSCLC cells harboring an activating EGFR mutation to generate . .. in EGFR (

mct.aacrjournals.org/content/5/5/1154SimilarMay 1, 2006 . Activating epidermal growth factor receptor (EGFR) mutations have . .. The EGFR

https://www.atcc.org/en/Products/. by. mutation/EGFR.aspxCachedThe identification of EGFR as an oncogene has made it a direct target for the

https://web.expasy.org/cellosaurus/CVCL_1483CachedSimilarResource Identification Initiative, To cite this cell line use: NCI-H1650 . in non-

“Three human NSCLC cell lines with an EGFR mutation of PC-9, HCC827 and

https://www.medscape.com/viewarticle/555203_3CachedOverall, the incidence of EGFR mutations in NSCLC among clinical . . and NCI-

https://www.neoplasia.com/article/S1476-5586(17)30048-9/pdfmin treatment in EGFR wild type (wt) HCC95 and H2122 cells, as well as EGFR

www.pnas.org/content/105/37/14112SimilarApproximately 90% of the lung cancer-specific EGFR mutations are equally . . 53

https://www.jstage.jst.go.jp/article/bpb/37/3/37_b13-00559/_pdfMar 1, 2014 . gefitinib sensitivity. We used four NSCLC cell lines-A549 (wild-type EGFR),

www.hal.inserm.fr/inserm-00602408/documentCachedJun 22, 2011 . 90% of EGFR mutations reported to date in lung adeno- carcinoma [3]. . The

aomf.ca/pdfs/Cancer%20Research.pdfCachedSimilarThree classes of EGFR mutations have been identified: an L858R missense . .

https://translational-medicine.biomedcentral.com/. /1479-5876-8-135CachedSimilarDetection of EGFR mutations with mutation-specific antibodies in stage IV non-

file2.selleckchem.com/. /BIBW-2992-Target-Oncol-20141029.pdfCachedOct 29, 2014 . NSCLC patients harbouring activated EGFR mutations. However . revealed that

www.jbc.org/content/early/2014/11/03/jbc.M114.585513.full.pdfCachedNov 3, 2014 . by Targeting Both Wildtype and L858R/T790M Mutant EGFR. Sung Keun Jung1

https://media.cellsignal.com/pdf/3197.pdfCachedSimilarof EGF receptor (EGFR) are present in a subset of lung adenocarinomas that .

https://cancer.sanger.ac.uk/cosmic/study/overview?paper_id. CachedThe egfr mutant NSCLC cell line H1650 as well as the egfr wild type cell lines

https://www.pamgene.com/. / AACR%202014%20%20%23%204248%20Izawa%20et%20al.pdfCachedSimilarMethods: Six lung cancer cell lines harboring either wild-type EGFR (A549 and

https://link.springer.com/article/10.1007/s00280-013-2132-ySimilarWe then focused on the gefitinib-resistant, EGFR mutant cell lines [H1650: exon

https://www.spandidos-publications.com/etm/13/6/3067/downloadgefitinib‑treated H1650 cells, while p‑EGFR levels decreased. By contrast, the .

onlinelibrary.wiley.com/doi/10.1111/cas.12237/pdfSimilarAug 20, 2013 . CH5164840 resulted in a significant level of dose-dependent antitumor activity in

https://astx.com/. //2013_AT13387_poster_IASLC-WCLC_abst_1791_ Hearn.pdfCachedBoth EGFR and its mutated forms are clients of HSP90 and are . EGFR. pEGFR.

https://www.researchgate.net/. /EGFR-mutated-human-lung-cancer-cell-lines- H1975-H1650-HCC827-were-treated-with-EGF_fig4_221772741Download scientific diagram| EGFR mutated human lung cancer cell lines (

www.martalive.org/attach/BioChemPharm_09.pdfCachedSimilarEGFR tyrosine kinase activity, such as gefitinib or erlotinib. The mammalian

https://www.tandfonline.com/doi/pdf/10.4161/cbt.8.6.7690Oct 20, 2008 . without EGFR mutations, including those harboring the T790M escape mutation.

erj.ersjournals.com/highwire/filestream/. /ERJ_-_R1_-_Supplement.pdfRNA is Favorable for Analyzing EGFR Mutations in Malignant Pleural . template

https://academic.oup.com/ajcp/article-pdf/126/4/. /ajcpath126-0608.pdfAnatomic Pathology / EGFR MUTATIONS IN NON–SMALL CELL LUNG

onlinelibrary.wiley.com/doi/10.1002/cncr.23100/pdfSimilarOct 19, 2007 . METHODS. Three NSCLC cell lines with varying EGFR mutation status and sensi

www.jto.org/article/S1556-0864(15)32081-5/fulltextSimilarPatterns of PCR-RFLP for EGFR Mutations on Gel-Electrophoresis . .. SK-MES-1,

https://www.sciencedirect.com/science/article/pii/S092544391500126XEpidermal growth factor receptor (EGFR) gene mutations are strongly associated with lung adenocarcinoma and favorable response to EGFR tyrosine kinase inhibitor. The mutated EGFR proteins (EGFRs) are hyper-phosphorylated and refractory to receptor down-regulation.

science.sciencemag.org/highwire/filestream/586015/. /Sordella.SOM.pdfSimilarGefitinib-sensitizing EGFR Mutations in Lung Cancer Selectively. Activate .

https://core.ac.uk/download/pdf/81991537.pdfCachedPATIENTS AND METHODS. Cell Lines and Plasmids Containing Wild-Type and

search.ebscohost.com/login.aspx?direct=true&profile. Title: Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a

https://pdfs.semanticscholar.org/. / d305659b7dfd4d424465799e0cc8f846b075.pdfCachedJan 15, 2008 . EGFR mutant cell lines, H3255 and HCC827, are sensitive to gefitinib, with IC50.

https://esmoopen.bmj.com/content/1/3/e000060SimilarHowever, most patients with EGFR-mutant NSCLC and treated with . . gefitinib

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4466647/SimilarFeb 5, 2015 . Various mechanisms of drug resistance have been identified in NSCLC for EGFR-TKIs treatment. Small in-frame deletions at exon 19 and point mutations within exon 21 (L858R) are the most common EGFR-activating mutations, which both lead to sustained kinase activity.

embomolmed.embopress.org/content/early/2018/02/. /emmm.201708313Feb 15, 2018 . In EGFR mutated Non‐Small Cell Lung Carcinoma with acquired . . Human

www.pxinc.com/assets/articles/Paper-4.PDFCachedSimilarThree classes of EGFR mutations have been identified an L858R . .. the

www.cell.com/cms/attachment/2053229638/2060116001/mmc3.pdfApr 14, 2016 . of EGFR-Mutant Cancers by Targeting Nuclear PKM2. Nan Li,1 . . whereas, in

journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed. CachedSimilarOct 30, 2007 . Abnormalities in EGF-EGFR signaling, such as mutations that render the . . H358

molecularmd.com/. /Absolute-Quantification-of-EGFR-Activation-and- Resistance-Mutations-by-Droplet-Digital-PCR-in-Circulating-Nuclei. CachedAbsolute Quantification of EGFR Activation and Resistance Mutations . Genomic

https://www.jci.org/articles/view/31871SimilarDec 3, 2007 . Therefore, mutant EGFR could activate the gp130/JAK/STAT3 pathway . . As can

https://orbi.uliege.be/. /1/1-s2.0-S0169500215300325-main.pdfCachedEGFR mutations in cancer cell proliferation and survival has been widely

molpharm.aspetjournals.org/content/87/5/832SimilarMay 1, 2015 . Whereas ectopic overexpression of PKCα in parental H1650 cells was not .

Sitemap